How many companies has Novo Nordisk A/S acquired?

Novo Nordisk A/S has made 3 documented acquisitions, with a combined disclosed deal value of $19.9B.

What was Novo Nordisk A/S's first major acquisition?

Novo Nordisk A/S's earliest documented acquisition in this dataset is Zenzedi (Actual Analytics) in 2019.

What is Novo Nordisk A/S's largest acquisition by deal value?

Novo Nordisk A/S's largest acquisition by disclosed deal value is Catalent (by Novo Holdings) in 2024, valued at $16.5B.

How much has Novo Nordisk A/S spent on acquisitions in total?

Novo Nordisk A/S has spent a combined disclosed total of $19.9B across its 3 documented acquisitions.

Novo Nordisk A/S

PharmaceuticalsFounded 1989

Reviewed by Swet Parvadiya

Last reviewed: July 2026

Explore Novo Nordisk A/S

Core profile pages, annual revenue records, and related research hubs for this company.

Novo Nordisk A/S

PharmaceuticalsFounded 1989

Reviewed by Swet Parvadiya

Last reviewed: July 2026

Acquisitions

Novo Nordisk A/S Acquisitions

Q: What is Novo Nordisk A/S's most recent acquisition?

Novo Nordisk A/S's most recent documented acquisition is Catalent (by Novo Holdings) in 2024. Novo Holdings acquired Catalent for $16.5 billion to secure three critical fill-finish facilities in Indiana, Belgium, and Italy, eliminating the physical supply constraints that limited Wegovy sales..

Total Acquisitions

$19.9B

Disclosed Deal Value

Catalent (by Novo Holdings)

2024

$16.5B

Why

Novo Holdings acquired Catalent for $16.5 billion to secure three critical fill-finish facilities in Indiana, Belgium, and Italy, eliminating the physical supply constraints that limited Wegovy sales.

Impact

The acquisition provided Novo Nordisk with immediate access to over 500,000 square feet of specialized biologics fill-finish capacity, allowing the company to accelerate the production of semaglutide and meet the estimated global demand for GLP-1 therapies.

Outcome

The integration is ongoing, with the facilities expected to be fully operational under Novo Nordisk's control by mid-2026. The acquisition demonstrates the company's strategy of vertical integration to control the entire value chain of peptide manufacturing.

Dicerna Pharmaceuticals

2021

$3.3B

Why

Novo Nordisk acquired Dicerna for $3.3 billion to gain control of its proprietary RNA interference (RNAi) technology platform, specifically the GalNAc conjugate technology for targeted liver delivery.

Impact

The acquisition established Novo Nordisk as a leader in the RNAi therapeutic modality, providing a novel platform for developing long-acting therapies for rare liver diseases and metabolic disorders.

Outcome

The integration has been successful, with several RNAi assets advancing through Phase I and II clinical trials. The acquisition demonstrates the company's strategy of acquiring early-stage platform technologies to expand its pipeline beyond peptide chemistry.

Zenzedi (Actual Analytics)

2019

$150M

Why

Novo Nordisk acquired Actual Analytics, a healthcare data analytics company, for $150 million to enhance its commercial intelligence and real-world evidence capabilities.

Impact

The acquisition provided Novo Nordisk with advanced data analytics tools to optimize its sales force deployment, track prescription trends, and identify unmet medical needs in the diabetes and obesity markets.

Outcome

The integration has been highly successful, with the Actual Analytics platform becoming a core component of the company's commercial strategy. The acquisition demonstrates the company's focus on leveraging data science to drive commercial execution.

Novo Nordisk A/S's Growth & Acquisition Strategy

Novo Nordisk A/S's growth strategy centers on this advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.

How Novo Nordisk A/S Makes Money

Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.

Related Companies

Eli Lilly and Company Novartis AG Bausch Health Companies Inc.

Compare Novo Nordisk A/S With Competitors

Novo Nordisk A/S vs Eli Lilly and Company Novo Nordisk A/S vs Novartis AG Novo Nordisk A/S vs Bausch Health Companies Inc.

Explore Novo Nordisk A/S

Core profile pages, annual revenue records, and related research hubs for this company.